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Abstract
E-cadherin is frequently lost during epithelial-mesenchymal transition and the progression of epithelial tumorigenesis. We
found a marker of epithelial-mesenchymal transition, CD44, upregulated in response to functional loss of E-cadherin in
esophageal cell lines and cancer. Loss of E-cadherin expression correlates with increased expression of CD44 standard
isoform. Using an organotypic reconstruct model, we show increased CD44 expression in areas of cell invasion is associated
with MMP-9 at the leading edge. Moreover, Activin A increases cell invasion through CD44 upregulation after E-cadherin
loss. Taken together, our results provide functional evidence of CD44 upregulation in esophageal cancer invasion.
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Introduction
CD44, or Indian blood group, is a transmembrane glycoprotein
and a receptor for hyaluronic acid (HA), a major component of the
extracellular matrix [1]. CD44 plays an important role in tissue
integrity and is involved in multiple functions associated with
cancer progression such as cell migration [2], resistance to
apoptosis [3] and presentation of growth factors and proteases
[4,5]. In addition, CD44 has been identified as a specific marker of
cancer stem cells [6,7] and of tumor cells undergoing an epithelial-
mesenchymal transition (EMT)-like process [8]. Different isoforms
are translated due to alternative splicing of exons 6–15 [9]. The
standard form of CD44 (CD44s) is thought to be ubiquitously
expressed, while some variant forms, CD44v, have been associated
with metastasis [10].
A major step of EMT is the loss of E-cadherin. E-cadherin is a
key component of adherens junctions and mediates cell adhesion
by interacting with the cytoplasmic proteins b-catenin [11] and
p120 [12]. Adherens junctions are connected to the actin
cytoskeleton through cytoplasmic linkers such as a-catenin [13].
E-cadherin can be transcriptionally repressed through Snail1,
Snail2, Twist, Zeb1 and Zeb2, which can be regulated by TGFb
[14]. Stimulation of breast cancer cells with TGFb results in co-
localization of the matrix metalloproteinase MT1-MMP and
CD44 at the cell membrane and induces CD44 cleavage resulting
in high levels of soluble CD44 [15]. Conversely, the interaction
between hyaluronan and CD44 modulates TGFb receptor
trafficking, which can regulate TGFb signaling [16].
During EMT, epithelial cells express markers such as CD44,
which are known to be expressed in cancer stem cells [8]. Activin
A has been shown to be a key regulator of stemness [17]. Activin
A, a member of the TGFb superfamily, has also been described to
affect development, hematopoiesis and tumorigenesis [18–24]. We
therefore wanted to determine whether Activin A induces EMT in
esophageal cells and thus links the induction of cell invasion to
Activin A and CD44 expression.
We have previously shown the coordinated loss of E-cadherin
and TGFb-receptor II (TGFbRII) in esophageal carcinoma [25].
OtherreportshaveindicatedtheimportanceofCD44inesophageal
squamouscarcinomademonstrating a higherexpressionofCD44v6
[26,27], but its impact on tumor invasion remains controversial.
Therefore, we aimed to study CD44 expression in esophageal
squamousepitheliuminvivoandinvitro.Inthepresentstudyweshow
that CD44 upregulation is associated with E-cadherin loss in
primary esophageal tumor tissues and cancer cell lines. Function-
ally, we demonstrate that Activin A signaling in the absence of E-
cadherin can upregulate CD44. Furthermore, CD44 anchors
MMP-9 to the invasive front translating into increased cell invasion.
These results have important implications for a novel role of Activin
A in the induction of EMT through upregulation of CD44.
Methods
Cell culture
Primary esophageal epithelial cells (keratinocytes) from normal
human esophagus were established as described previously [25]. In
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full-length E-cadherin or a dominant-negative mutant of E-
cadherin lacking the cytoplasmic tail (designated as EC) were used
for transfection of hTERT-immortalized, but non-transformed,
esophageal epithelial cells [28]. Empty pFBneo was used as a
control. Additionally, a dominant-negative mutant of TGFbRII (a
gift of Dr. H. Moses, Vanderbilt University, Nashville, TN),
subcloned into pBABE puro, was used to generate ECdnT cells
and empty pBABE puro as a control. Full-length E-cadherin in
pFBneo was also used to restore E-cadherin expression in TE-8
and FLO-1 cells. Fetal esophageal fibroblasts were grown in
DMEM with 10% fetal bovine serum (FBS, Hyclone, Thermo
Fisher Scientific, Waltham, MA), 100 units/mL penicillin, and
100 mg/mL streptomycin (Gibco, Invitrogen, Carlsbad, CA). The
esophageal squamous carcinoma cell lines, TE cells, were a kind
gift from Drs. Rustgi and Nakagawa (University of Pennsylvania,
Philadelphia, PA). Esophageal adenocarcinoma cell lines OE33,
FLO-1 and SK-GT-4 [29–31] and the head and neck cancer cell
lines JHU-012 and JHU-013 were developed from primary head
and neck squamous cell carcinoma in the Division of Head and
Neck Cancer Research at the Johns Hopkins University.
For E-cadherin inhibition, cells were seeded at a density of 2x
10
5 cells per well in a 6- well plate. After 24 hours, medium was
changed to serum-free DMEM and cells were transfected with a
final concentration of 10 nM siRNA using calcium phosphate
transfection (400 mL of RNAse-free water was mixed with 50 mL
2.5 M CaCl2,5 0mLo f2mM siRNA with 500 mL of HBSP2x
(280 mM NaCl, 1.5 mM NA2PO42H2O, 12 mM glucose, 10 mM
KCL, 50 mM HEPES pH7.05 in 500 mL RNAse-free water)).
siRNA were obtained from Qiagen (Qiagen, Valencia, CA), Hs-
CDH1_12 (si1) and Hs_CDH1_13 (si2) were used against E-
cadherin and AllStars negative, non-silencing siRNA probes were
used for control (ctrl). For stimulation, 20 ng/ml of Activin A
(R&D, Minneapolis, MN) was added to the culture.
Tissue microarrays
Esophageal squamous carcinoma tissues were procured via
surgery at the Okayama University Hospital, Kitano Hospital and
the Hospital of the University of Pennsylvania through the
Cooperative Human Tissue Network (CHTN). All were patho-
logically diagnosed as esophageal squamous cell carcinoma
(ESCC) [32]. Additionally, a commercial tissue array for ESCC,
AccuMax Array (ISU ABXIS, Co., distributed by Accurate
Chemical & Scientific Corp., Westbury, NY) that contains 80
esophageal squamous cancer formalin fixed paraffin embedded
(FFPE) tissues from 40 patients and 4 normal controls was used for
immunhistochemical staining. Together, data could be collected
for 166 squamous tumor samples, 2 cases with the progression
from normal, carcinoma in situ to ESCC, and additional normal
tissue controls.
One-hundred-and-thirty-three esophageal adenocarcinoma
(EAC) FFPE samples were analyzed after immunohistochemical
staining. These samples were obtained from the archives of the
departments of pathology at Vanderbilt University (Nashville, TN,
USA), Otto-von-Guericke University (Magdeburg, Germany) and
from the CHTN [33]. Histopathological diagnosis of Barrett’s
esophagus, dysplasia and esophageal adenocarcinoma was verified
on the basis of H&E-stained sections according to the Vienna
classification of gastrointestinal epithelial neoplasia [34]. Immu-
nohistochemistry staining was performed using anti-pan CD44
antibody, clone F10-44-2, and anti-E-cadherin antibody, clone 36.
Expression scored on a scale from 0 to 3 with 0 being absent, and
3 being the highest signal intensity, and membranous or
cytoplasmic localization of staining was recorded. Samples with
scores of 1 or higher and with membranous localization were
considered positive. For statistical analysis positive signals
regardless of the intensity were considered positive and scores
below 1 as negative and statistically analyzed using 262
contingency tables and Fisher’s exact test.
Organotypic culture
Organotypic cultures were grown as described previously [25].
In brief, human esophageal epithelial cells (keratinocytes) were
seeded onto a 3:1 collagen I/matrigel layer with 7.5610
4 human
fetal esophageal fibroblasts embedded. Collagen I was purchased
from Organogenesis (Canton, MA) and Matrigel Matrix from BD
Bioscience (Franklin Lakes, NJ). On day 11, cultures were raised to
an air–liquid interface to induce differentiation of the epithelium.
Cultures were harvested on day 15 and either fixed in 10%
formaldehyde (Fisher, Pittsburg, PA) for paraffin embedding or
directly embedded into Tissue-Tek O.C.T. compound (VWR,
Batavia, IL) for frozen sections.
Cell Invasion Assays
Invasion assays were performed as previously described [25]
using 8 mm pore size Biocoat Matrigel Fluoroblok invasion
chambers (BD Biosciences, Franklin Lakes, NJ). Epithelial cells
(5610
4 per chamber) were seeded into the transwell inserts and the
invading cells stained with Calcein AM (Invitrogen, Carlsbad, CA)
after overnight incubation. Activin A was added with a
concentration of 20 ng/ml as a chemoattractant. Invasion was
quantified using the Multimode Plate Reader Synergy HT (Bio-
Tek, Winooski, VT). All experiments were done in triplicate and
repeated twice. Data are presented as mean6SD. Man and
Whitney test was performed for statistical analysis.
Antibodies
CD44 Hermes-III (a kind gift from Dr. Ellen Pure, Wistar
Institute, Philadelphia, PA) was used for immunofluoresence on
frozen sections; anti-CD44 clone 2C5 (R&D systems, Minneapolis,
MN) for Western Blot; CD44 F10-44-2 and a-tubulin (Abcam,
Cambridge, MA) were used for immunohistochemistry on FFPE
and Western Blot, respectively; E-cadherin purchased from BD
Bioscience (Franklin Lakes, NJ), b-actin and aSMA clone 1A4
were both purchased from Sigma (Saint Louis, MO), anti-MMP-9
from Calbiochem (EMD Chemicals, Rockland, MA); S100A4 is
from Thermo Fisher Scientific (Fremont, CA) and vimentin clone
V9 from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed with the Vecta Elite kit
(Vector Laboratories, Burlingame, CA) following the manufactur-
er’s protocol using their reagents. Primary antibody was incubated
overnight at 4uC and secondary antibody for 30 minutes at 37uC.
Then, the signal was developed using the DAB substrate kit for
peroxidase. For immunofluoresence staining, a biotinylated
secondary antibody was detected using Texas-Red-Streptavidin
or FITC-label secondary antibody. Stained sections were mounted
with DAPI-containing mounting medium.
Zymography and in situ zymography
Conditioned media from organotypic culture grown under
serum-free conditions for 48 hours were separated on a 10%
acrylamide gel containing gelatin at 4uC. Gels were stained with
Coomassie blue R250 for 2 hours and excess of coloration was
removed with destain buffer (10% acetic acid 20% methanol).
Images were taken using Gel Doc
TM XR (Bio Rad, Hercules, CA).
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(Molecular Probes, Invitrogen, Carlsbad, CA) was resuspended in
1 ml deionized water at a concentration of 1 mg/ml. 100 ug/ml
DQ-Gelatin was used to overlay 5 micron thick frozen sections of
organotypic cultures for 18 hours at 37uC. The fluorescein signal
on the sections was imaged using a fluorescence microscope (Zeiss,
Thornwood, NY).
Western blotting
Western Blots were performed as described before [35].
Experiments were repeated at least twice.
Results
Primary human esophageal tumors show inverse
expression of E-cadherin and CD44
To determine the role of CD44 in esophageal cell invasion and
EMT, we performed immunohistochemical staining of E-cadherin
and CD44 on tissue microarrays of 166 squamous cell carcinoma
(SCC) and 131 adenocarcinomas. For two esophageal SCC
patients, samples representing the progression from normal to
carcinoma in situ (CIS) and subsequently ESCC (Fig. 1A to 1C), we
observed a gradual increase of CD44 expression. Overall, E-
cadherin was largely restricted to areas with low or absent CD44
expression in the normal epithelium (Fig. 1D, E) and 20 out of 166
tumors. For esophageal SCC, we observed upregulation of CD44
in the absence of E-cadherin in 54% of the tumors (90 out of 166
tumors). Together, 110 out of 166 (66%, p,0.02) of our clinical
samples displayed this inverse relationship of E-cadherin and
CD44. Esophageal adenocarcinoma samples showed an inverse
correlation of E-cadherin and CD44 expression in 63 out of 131
samples (48%), with 41 samples having substantial E-cadherin, but
no CD44 expression. Twenty-two samples had increased CD44
expression and are negative for E-cadherin. Taken together, we
show a statistical significant (p,0.05) inverse correlation for the
expression of E-cadherin and CD44. Images of representative
immunohistochemical stainings of tumor tissues demonstrating the
association of E-cadherin and CD44 are shown in Fig. 1 F-I.
E-cadherin-negative esophageal cancer cell lines show
increased CD44 expression
To investigate the inverse correlation of E-cadherin with CD44
in esophageal cancer cell lines, we analyzed esophageal squamous
cell carcinoma cell lines (TE-1, -7, -8, -11 and -12), head-and-neck
squamous cancer cell lines (JHU-012, JHU-013), as well as
adenocarcinoma cell lines (FLO-1, OE33 and SK-GT-4) by
Western Blot for E-cadherin and CD44 expression as well as
TGFbRII and vimentin. While the standard form of CD44
(CD44s) is expressed in mesenchymal cells, some variant forms,
CD44v, are expressed in epithelial cells [36]. We found that cells
retaining E-cadherin expression had lower levels of standard
(85 kDa due to the lack of exon 6–15) and the variant form
(150 kDa) of CD44. The loss of E-cadherin correlates with the
increased expression of CD44s and an increase in expression of the
EMT marker vimentin (Fig. 2A). To determine if restoration of E-
cadherin can affect the expression of CD44s and CD44v, we
transfected TE-8 and FLO-1 cell lines, both express low levels of
E-cadherin, with full-length E-cadherin. Upon restoration of E-
cadherin expression, the overall level of CD44 expression was
decreased, but the variant (epithelial) form (125 kDa) increased
(Fig. 2B).
CD44 expression is upregulated in esophageal epithelial
cells undergoing EMT
We previously established a model to analyze the effects of E-
cadherin loss on esophageal keratinocytes by retroviral expression
of dominant-negative E-cadherin (EC) or dominant-negative E-
cadherin in combination with dominant-negative TGFbRII
(ECdnT) [25]. We performed immunohistochemical stainings
with antibodies against E-cadherin and CD44 and markers of
EMT to elucidate the role of CD44 in esophageal EMT and cell
invasion. EC and ECdnT cells have upregulated CD44 expres-
Figure 1. Inverse correlation of E-cadherin and CD44 expression in primary human esophageal tumors. IHC with anti-CD44 antibody
shows increased CD44 expression during the progression from normal (A) to carcinoma in situ, CIS (B), and tumor (C). Antibody against E-cadherin
and CD44 show expression of E-cadherin (D) and in the absence of CD44 (E) in the normal epithelium. In EAC tissues with retained E-cadherin
expression (F, dashed black line) the signal for CD44 is low (G). (H) Loss of E-cadherin is associated with an intense signal for CD44 (I). Scale bar is 50
micron.
doi:10.1371/journal.pone.0027063.g001
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epithelial cell invasion into the underlying matrix (Fig. 3). Both EC
and ECdnT cells have increased levels of S100A4, vimentin and
aSMA indicating that these cells are undergoing EMT in
organotypic cultures (Fig. 3D–F).
CD44 co-localizes with MMP-9 at the leading edge of
invasive areas and is upregulated by Activin A
To analyze the mechanism by which CD44 mediates cell
invasion we focused on the activation of matrix metalloproteinases,
prominent proteases digesting the extracellular matrix. To
visualize MMP activity in areas of invasion we used in situ
zymography. Fluorescein-positive areas detecting MMP activity
were restricted to the leading edge in EC and ECdnT cells and cell
invasion into the underlying matrix (Fig. 4A). Conditioned media
from organotypic cultures showed a gradual increase of MMP-9
secretion and MMP-2 and MMP-9 activity in the invasive cells
(Fig. 4B). MMP-9 has been described as a binding partner of
CD44 [37,38]. Using double immunofluoresence staining with
antibody against CD44 and MMP-9 we illustrate their co-
localization at the cell surface on the leading edge of invasive
areas (Fig. 4C). To demonstrate an increased invasive potential in
response to Activin A, a TGFb family member, secretion of which
is increased in the invasive organotypic cultures (data not shown),
we stimulated ECdnT cells and the esophageal cancer cell line TE-
11 and show enhanced cell invasion in vitro (Fig. 4D).
Activin A has also been described to regulate stemness [17] and
we hypothesized that CD44 as a stem cell marker might be under
the regulation of Activin A. To identify a potential signaling
pathway responsible for the upregulation of CD44, we analyzed
the esophageal cancer cell line, TE-11, after knockdown of E-
cadherin using siRNA. We stimulated TE-11 cells transfected with
siRNA against E-cadherin cells with Activin A and analyzed the
expression of CD44. Activin A treatment increased CD44 variant
expression in TE-11 in the absence of E-cadherin (Fig. 4E).
Taken together, these data demonstrate the regulation of CD44
expression by E-cadherin through Activin A and provide
functional evidence for a causal role in the induction of cell
invasion.
Discussion
We show the gradual loss of E-cadherin is associated with a
progressive increase of CD44 in vitro and in vivo. In the absence of
E-cadherin, Activin A can induce CD44 expression. Activin A was
shown to be a key regulator for stemness [17] and like other
members of the TGFb superfamily, has also been reported to
affect development and tumorigenesis [20,22–24]. Overexpression
of Activin A has been described in esophageal squamous cell
carcinoma and is associated with poor prognosis. Activin A
promotes tumor cell aggressiveness by increased expression of
MMP-7 and N-cadherin [22–24]. Here we show that Activin A
can upregulate CD44, which in turn anchors MMP-9 to the
leading edge and induces cell invasion. The association of E-
cadherin, CD44 and MMPs with EMT suggests a major role for
Activin A in EMT.
We found that E-cadherin loss is accompanied by a change of
CD44 isoform expression. Although previous studies have shown
that alternative splicing of CD44 could be controlled through ras
signaling to promote expression of variant forms [39], Warzecha et
al. have recently identified epithelial splicing factors (ESRP1 and
ESRP2) promoting the expression of CD44v to maintain the
epithelial phenotype [40]. Those factors are lost during EMT [41–
43]. Conceivably, expression of standard CD44 is dependent on
loss of ESRP1 and 2 in esophageal carcinoma. ESRP1 and 2
expression has been further recognized to be implicated in EMT-
associated splicing programs in breast cancer [44]. Interestingly,
silencing of ESPR1/2 in epithelial cells induced expression of the
mesenchymal cadherin, N-cadherin, without changes in E-
cadherin expression. Conversely, expression of ESPR1 can reverse
Twist-induced EMT in mammary epithelial cells. In addition, the
transcription factor Twist2 contributes to the expansion of stem-
like cell populations through downregulation of E-cadherin and
increased expression of stem cell markers such as CD44 [45].
Taken together, there are multiple mechanisms by which CD44
isoforms, all share the same cytoplasmic domain, can induce
EMT, many of which involve the interaction of the extracellular
domain with the microenvironment. CD44 can act as a co-
receptor for c-Met and is the bona fide receptor for hyaluronic
acid, which can promote EMT [9]. E-cadherin negatively
regulates the interaction of CD44 with hyaluronic acid resulting
Figure 2. Expression of CD44, TGFbRII, vimentin and E-
cadherin in cancer cell lines. (A) Western Blot analysis of esophageal
squamous carcinoma cell lines (TE-1 -7, -8, -11, and -12), esophageal
adenocarcinoma cell lines (FLO-1, OE33, SK-GT-4) and head and neck
cancer cell lines (JHU-012, JHU-013) show that expression of E-cadherin
and TGFbRII is associated with low levels of CD44, while loss of E-
cadherin and TGFbRII correlates with up-regulation of CD44 and the
EMT marker vimentin. (B) Restoration of E-cadherin, Ecad, expression by
retroviral transfection of TE-8 and FLO-1 cells compared to vector
control (neo) demonstrates an overall decrease in CD44 expression
along with a switch to increased CD44v over CD44s (CD44v:
CD44variant, CD44s: CD44 standard).
doi:10.1371/journal.pone.0027063.g002
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genesis [46]. We show here that the loss of E-cadherin expression
correlates with the CD44s form and induction of an invasive
phenotype.
We have previously shown that the invasion of esophageal
keratinocytes lacking functional E-cadherin and TGFbRII was
mediated by cathepsin B [35]. Cathepsin B can be activated in
an acidic environment initiated by the interaction of CD44 with
aN a +-H+ exchanger [37]. While increased cathepsin B activity
results in TGFb activation [35], MMP-9 can also activate
TGFb [47] linking the data presented here with our previous
study. Paracrine TGFb signaling activates fibroblasts, and also
induces capillary formation [48]. These observations highlight
the importance of the epithelial-mesenchymal crosstalk in
tumorigenesis.
In conclusion, we show that CD44 upregulation is associated
with the loss of E-cadherin in esophageal carcinoma and that
CD44 promotes MMP-9 mediated tumor invasion.
Figure 3. CD44 expression is increased in areas of invasion after E-cadherin loss. Immunohistochemistry of paraffin sections with anti-E-
cadherin antibody (A), anti-TGFbRII (B) and anti-CD44 (C) shows CD44–positive cells in EC and ECdnT cells invading into the underlying collagen/
matrigel matrix (arrows) that are negative for E-cadherin and TGFbRII. Immunohistochemical staining for the EMT markers S100A4 (D), vimentin (E)
and aSMA (F) shows increased positive signal in invading cells. Scale bar is 50 micron.
doi:10.1371/journal.pone.0027063.g003
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